AN1.AU Anagenics Ltd
- Market cap
- AUD 4.93M
- P/E
- -
- P/B
- 1.17x
- ROE
- 7.3%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is AN1.AU undervalued?
Graham numberThe Graham number of Anagenics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anagenics Ltd fundamental analysis
9 of 22 checks passedROE 0/2
Low return on equity (7.3%), below 10%.
ROA 1/1
Return on assets (6.5%) is above the industry median (-30.2%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (115.8%) is above the industry median (-11.1%).
Revenue Growth 0/2
Revenue shrank 17.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.8%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 9.1x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.2x) is below the industry median (6.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Anagenics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anagenics Ltd
Anagenics Limited engages in the health, wellness, and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed it…
Full company profileAnagenics Ltd financial statements
Anagenics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.50M | 5.65M | 7.30M | 7.38M | 5.82M | 6.95M | 9.11M | 10.8M | 4.75M | 5.16M |
| Gross Profit | -331K | 27.9K | 5.16M | 4.85M | 3.70M | 3.80M | 4.05M | 4.36M | 2.04M | 2.81M |
| Operating Income | -4.14M | -3.26M | -5.65M | -4.75M | -3.64M | -1.60M | -1.92M | -7.38M | -1.32M | 630K |
| EBITDA | -3.99M | -3.07M | -5.50M | -4.23M | -3.90M | -2.22M | -1.80M | -6.60M | -995K | 816K |
| Net Income | -4.47M | -3.73M | -5.91M | -4.91M | -3.39M | -3.65M | -2.67M | -7.49M | -1.24M | 308K |
| EPS | -0.08 | -0.06 | -0.07 | -0.05 | -0.02 | -0.02 | -0.01 | -0.02 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 8.47M | 6.75M | 9.79M | 14.9M | 13.3M | 12.9M | 11.1M | 6.19M | 4.10M | 4.75M |
| Total Liabilities | 4.08M | 4.89M | 3.93M | 5.08M | 2.86M | 4.64M | 2.22M | 3.48M | 2.28M | 521K |
| Shareholders' Equity | 4.40M | 1.86M | 5.86M | 9.81M | 10.4M | 8.29M | 8.90M | 2.71M | 1.83M | 4.23M |
| Cash & Short-term Investments | 3.99M | 1.61M | 3.08M | 6.97M | 6.73M | 3.28M | 2.57M | 1.62M | 396K | 577K |
| Total Debt | 2.16M | 3.17M | 1.29M | 1.96M | 1.43M | 1.76M | 654K | 773K | 848K | 33.2K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.06M | -4.40M | -5.93M | -4.01M | -4.11M | -2.53M | -1.78M | -1.74M | -1.58M | -1.07M |
| Capital Expenditure | 35.9K | 107K | 65.7K | 22.5K | 22.5K | 35.9K | 45.4K | 97.9K | 3.00 | 25.0K |
| Free Cash Flow | -4.10M | -4.51M | -6.00M | -4.01M | -22.5K | -2.59M | -1.83M | -1.84M | -1.58M | -1.09M |
| Ratios | ||||||||||
| ROE | -101.7% | -201.2% | -100.9% | -50.0% | -32.5% | -44.0% | -30.0% | -276.5% | -67.7% | 7.3% |
| ROA | -52.8% | -55.3% | -60.4% | -33.0% | -25.5% | -28.2% | -24.0% | -121.0% | -30.1% | 6.5% |
| Net Profit Margin | -99.4% | -66.1% | -80.9% | -66.5% | -58.2% | -52.5% | -29.3% | -69.4% | -26.0% | 6.0% |
| Debt to Equity | 0.49x | 1.71x | 0.22x | 0.20x | 0.14x | 0.21x | 0.07x | 0.29x | 0.46x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anagenics Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 271K | 0.00 | - |
| 2022 | - | - | - |
| 2021 | AUD 54.8K | 0.00 | - |
| 2020 | AUD 202K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Nov 27, 2017.
Who owns Anagenics Ltd
- Insiders 52.36%
- Institutions 0.00%
- Public & others 47.64%
- Shares outstanding 985M
- Free float 464M
Anagenics Ltd company profile
- Company name
- Anagenics Ltd
- Ticker
- AN1.AU
- ISIN
- AU0000198095
- Exchange
- Australian Securities Exchange
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Fiscal year end
- June
- Address
- 55 Clarence Street, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9221 6830
- Website
- anagenics.com
About Anagenics Ltd
Anagenics Limited engages in the health, wellness, and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
Anagenics Ltd management
2- Mr. Michael WornerChief Financial Officer
- Dr. Graham RobertsonHead of Research & Development